LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Titel:
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Auteur:
Prat, A. Falato, C. Pare Brunet, L. Martinez Saez, O. Cejalvo Andujar, J.M. Margeli Vila, M. Tolosa, P. Salvador Bofill, F.J. Cruz Jurado, J. Gonzalez-Farre, B. Sanfeliu Torres, E. Ciruelos, E.M. Espinosa-Bravo, M. Izarzugaza Peron, Y. Pernas Simon, S. Esker, S. Fan, P-D. Ferrero Cafiero, J.M. Pascual, T. Oliveira, M.